Potential hazards of combination immunotherapy in the treatment of experimental septic shock

Journal of Infectious Diseases

Volumn 173, Issue 6, 1996, Pages 1415-1421

  Opal, Steven M ^a   Cross, Alan S ^b   Jhung, Jhung W ^b   Young, Lynnette D ^b   Palardy, John E ^b   Parejo, Nicholas A ^b   Donsky, Curtis ^b  

^a BROWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENDOTOXIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROGOL; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENDOTOXEMIA; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SEPTIC SHOCK; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

EID: 0029825062     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.6.1415     Document Type: Article

References (13)

1. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia - United States: 1979-1987. MMWR 1990;39: 31-4.
2. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-69.
3. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991;63:1177-84.
4. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bactercmia. Nature 1987; 330:662-4.
5. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:868-72.
6. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990;30:279-92.
7. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. An interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-2.
8. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival in hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89:1551-7.
9. Wakabayashi G, Gelfand JE, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin-1 prevents Escherichia coliinduced shock in rabbits. FASEB J 1991;5:338-43.
10. Fisher CJ Jr, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-27.
11. Abraham E, Wunderlink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome. JAMA 1995;273:934-41.
12. Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-labelled, placebo-controlled trial. Crit Care Med 1994;22:12-21.
13. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome, results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1863-93.